Related Experiment Video
Updated: May 1, 2026
04:47
Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
Published on: October 27, 2023
2.2K
Association between KIR polymorphisms and ankylosing spondylitis in populations: a meta-analysis
1Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University , Hefei, Anhui , P. R. China.
Modern Rheumatology
|March 29, 2014
Summary
This meta-analysis suggests killer cell immunoglobulin-like receptor (KIR) polymorphisms 2DS4 and 3DS1 are potential risk factors for ankylosing spondylitis (AS). Findings varied by ethnicity and HLA-B*27 status.
Area of Science:
- Immunogenetics
- Rheumatology
- Population Genetics
Background:
- Published studies on killer cell immunoglobulin-like receptor (KIR) polymorphisms and ankylosing spondylitis (AS) susceptibility show inconsistent results.
- Understanding the genetic factors influencing AS pathogenesis is crucial for developing targeted therapies.
Purpose of the Study:
- To conduct a meta-analysis to determine if KIR polymorphisms are associated with AS susceptibility in various populations.
- To clarify the conflicting findings from previous association studies.
Main Methods:
- A comprehensive literature search was performed across major databases (PubMed, Elsevier, CNKI, CBM) up to August 2013.
- Included 13 case-control studies from 9 articles investigating the association between KIR polymorphisms and AS.
- Calculated odds ratios (OR) with 95% confidence intervals (95%CI) to assess the strength of association.
Main Results:
- The meta-analysis identified significant positive associations between KIR 2DS4 and 3DS1 polymorphisms and AS susceptibility.
- Subgroup analyses revealed ethnicity-specific associations: KIR 2DS4 with AS in Asians, and KIR 3DL1/3DS1 in Caucasians.
- Associations were also observed between several KIR genes (2DL5, 2DS4, 2DS5, 3DL1, 3DS1) and AS in HLA-B*27-positive individuals.
Conclusions:
- KIR 2DS4 and 3DS1 polymorphisms are confirmed as potential risk factors for ankylosing spondylitis in the studied populations.
- These findings highlight the role of specific KIR genes in AS pathogenesis, with variations across ethnic groups and in relation to HLA-B*27 status.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
12.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.6K
01:20The JAK-STAT Signaling Pathway
10.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.2K
01:05Single Nucleotide Polymorphisms-SNPs
14.6K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.6K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159